Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 6/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1709717 | 0.98 | GHSR (0.57) | GHSREPHX1HPGDNPC1RAB9A | |
| SCHEMBL10121684 | 0.97 | GHSR (0.59) | GHSREPHX1HPGDNPC1RAB9A | |
| SCHEMBL10121950 | 0.89 | GHSR (0.64) | GHSREPHX1EPHX2SMN1; SMN2GAA | |
| SCHEMBL10121689 | 0.88 | GHSR (0.61) | GHSREPHX2SMN1; SMN2GAA | |
| SCHEMBL10121851 | 0.88 | GHSR (0.56) | GHSREPHX1SMN1; SMN2GAA | |
| SCHEMBL1709682 | 0.88 | GHSR (0.62) | GHSRHPGDTP53TSHROPRM1 | |
| SCHEMBL10121678 | 0.87 | GHSR (0.59) | GHSRRAB9ATSHROPRM1GAA | |
| SCHEMBL1709719 | 0.87 | GHSR (0.61) | GHSRHPGDTP53TSHROPRM1 | |
| SCHEMBL1709620 | 0.87 | GHSR (0.56) | GHSRSMN1; SMN2CCR5KMT2AGAA | |
| SCHEMBL10122191 | 0.87 | GHSR (0.56) | GHSRHPGDTSHRKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | GHSR 1/4885EPHX1 2690/4885HPGD 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.